Climb Bio, Inc. - 8-K Filing
Climb Bio announces initial Phase 2 PrisMN data for budoprutug showing 70% mean PLA2R antibody reduction at Week 12 in the 200 mg cohort. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)